Molecular Templates, Inc.

Equities

MTEM

US6085502085

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
1.64 ^USD	+5.81%		+3.80%	-56.03%

Apr. 12	Molecular Templates, Inc. Announces Cessation of Maurizio Voi as Chief Medical Officer, Effective April 30, 2024	CI
Apr. 09	Molecular Templates, Inc. Presents Interim Data from Mt-6402 Phase I Study in Patients with Pd-L1+ Solid Tumors At the 2024 American Association for Cancer Research Annual Meeting	CI

Threshold Pharmaceuticals : Summary ToggleMolecular Templates to Present at the 2017 BIO Investor Forum

October 06, 2017 at 08:15 am EDT

AUSTIN, Texas, Oct. 06, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, today announced that Eric E. Poma, Ph.D., Chief Executive and Chief Scientific Officer, will provide a corporate overview at the 2017 BIO Investor Forum, being held October 17-18 in San Francisco, California.

BIO Investor Forum
Date: Tuesday, October 17
Time: 10:30am Pacific Time
Location: Westin St. Francis, San Francisco, Elizabethan C Ballroom
Webcast: http://www.veracast.com/webcasts/bio/investorforum2017/25111335172.cfm

About Molecular Templates
Molecular Templates is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases. For additional information, please visit Molecular Templates' website at www.mtem.com .

Investor Contact:Andrew McDonald, Ph.D.
andrew@lifesciadvisors.com
646-597-6987

Source: Molecular Templates

Molecular Templates Inc. published this content on 06 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 06 October 2017 12:14:04 UTC.

Original documenthttp://ir.mtem.com/news-releases/news-release-details/molecular-templates-present-2017-bio-investor-forum

Public permalinkhttp://www.publicnow.com/view/D25271F47FC85B7A77146ACFA32A552E269391D5

Latest news about Molecular Templates, Inc.

Molecular Templates, Inc. Announces Cessation of Maurizio Voi as Chief Medical Officer, Effective April 30, 2024	Apr. 12	CI
Molecular Templates, Inc. Presents Interim Data from Mt-6402 Phase I Study in Patients with Pd-L1+ Solid Tumors At the 2024 American Association for Cancer Research Annual Meeting	Apr. 09	CI
Molecular Templates, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Molecular Templates, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 29	CI
North American Morning Briefing: Investors Balance AI Hopes with Rate Concerns	Mar. 18	DJ
Molecular Templates, Inc. Provides Interim Update	Mar. 04	CI
Molecular Templates, Inc. Announces Board Changes	Jan. 17	CI
Molecular Templates, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Earnings Flash (MTEM) MOLECULAR TEMPLATES Reports Q3 Revenue $6.8M	Nov. 13	MT
Molecular Templates, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors	Nov. 02	CI
Molecular Templates Names Chief Medical Officer	23-09-28	MT
Molecular Templates, Inc. Announces Chief Medical Officer Changes, Effective as of October 2, 2023	23-09-28	CI
Molecular Templates' Board Approves 1-for-15 Reverse Stock Split	23-08-11	MT
Molecular Templates, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Earnings Flash (MTEM) MOLECULAR TEMPLATES Reports Q2 Revenue $6.9M	23-08-10	MT
Molecular Templates Names Interim Chief Medical Officer, Other Executives	23-08-03	MT
Molecular Templates, Inc. Announces Executive Changes	23-08-02	CI
Molecular Templates, Inc. Announces Jason Kim Assumes the Role of Chief Financial Officer	23-08-02	CI
Molecular Templates Signs Deal for Up to $40 Million Private Placement	23-07-13	MT
Molecular Templates, Inc. announced that it expects to receive $40 million in funding	23-07-12	CI
Molecular Templates, Inc.(NasdaqCM:MTEM) dropped from Russell Microcap Value Index	23-06-23	CI
Molecular Templates, Inc.(NasdaqCM:MTEM) dropped from Russell 3000E Value Index	23-06-23	CI
Molecular Templates, Inc.(NasdaqCM:MTEM) dropped from Russell Microcap Growth Index	23-06-23	CI
Molecular Templates, Inc.(NasdaqCM:MTEM) dropped from Russell Microcap Index	23-06-23	CI
Molecular Templates, Inc.(NasdaqCM:MTEM) dropped from Russell 3000E Growth Index	23-06-23	CI

Chart Molecular Templates, Inc.

Duration

Period

More charts

Company Profile

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. The Companyâs proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Molecular Templates, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.64 USD

Average target price

18 USD

Spread / Average Target

+997.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MOLECULAR TEMPLATES, INC.	-56.03%	8.33M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	105B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.5B
ARGENX SE	+1.86%	22.19B
BIONTECH SE	-16.53%	21.33B
GENMAB A/S	-8.49%	18.68B
WUXI APPTEC CO., LTD.	-42.33%	16.6B
BEIGENE, LTD.	-20.09%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	14.09B
SAREPTA THERAPEUTICS, INC.	+28.85%	10.99B

Bio Therapeutic Drugs